Table III.
Immunohistochemical expression of CXCL2 and TANs in 119 samples with strong staining for Porphyromonas gingivalis from patients with oral squamous cell carcinoma according to clinical data and follow-up.
| CXCL2 | TANs | |||||
|---|---|---|---|---|---|---|
| Variable | Weak, n (%) | Strong, n (%) | P-value | Weak, n (%) | Strong, n (%) | P-value |
| Sex | 0.631 | 0.824 | ||||
| Male | 15 (50.0) | 49 (55.1) | 21 (55.3) | 43 (53.1) | ||
| Female | 15 (50.0) | 40 (44.9) | 17 (44.7) | 38 (46.9) | ||
| Age, years | 0.038a | 0.229 | ||||
| <60 | 15 (50.0) | 26 (29.2) | 16 (42.1) | 25 (30.9) | ||
| ≥60 | 15 (50.0) | 63 (70.8) | 22 (57.9) | 56 (69.1) | ||
| Survival status | 0.003a | 0.226 | ||||
| Alive | 25 (83.3) | 47 (52.8) | 26 (68.4) | 46 (56.8) | ||
| Dead | 5 (16.7) | 42 (47.2) | 12 (31.6) | 35 (43.2) | ||
| Differentiation | 0.279 | 0.556 | ||||
| Well | 20 (66.7) | 48 (53.9) | 24 (63.2) | 44 (54.3) | ||
| Moderate | 8 (26.7) | 25 (28.1) | 10 (26.3) | 23 (28.4) | ||
| Poor | 2 (6.7) | 16 (18.0) | 4 (10.5) | 14 (17.3) | ||
| Tobacco consumption | 0.628 | 0.460 | ||||
| Yes | 9 (30.0) | 31 (34.8) | 11 (28.9) | 29 (35.8) | ||
| No | 21 (70.0) | 58 (65.2) | 27 (71.1) | 52 (64.2) | ||
| Alcohol consumption | 0.189 | 0.158 | ||||
| Yes | 7 (23.3) | 17 (19.1) | 5 (13.2) | 19 (23.5) | ||
| No | 23 (76.7) | 72 (80.9) | 33 (86.8) | 62 (76.5) | ||
| T stageb | 0.023a | 0.015a | ||||
| T1-2 | 21 (70.0) | 41 (46.1) | 26 (68.4) | 36 (44.4) | ||
| T3-4 | 9 (30.0) | 48 (53.9) | 12 (31.6) | 45 (55.6) | ||
| N stageb | 0.091 | 0.053 | ||||
| N0 | 23 (76.7) | 53 (59.6) | 29 (76.3) | 47 (58.0) | ||
| N(+) | 7 (23.3) | 36 (40.4) | 9 (23.7) | 34 (42.0) | ||
| Clinical stage | 0.093 | 0.002a | ||||
| I–II | 16 (53.3) | 32 (36.0) | 23 (60.5) | 25 (30.9) | ||
| III–IV | 14 (46.7) | 57 (64.0) | 15 (39.5) | 56 (69.1) | ||
| Recurrence | 0.589 | 0.075 | ||||
| Yes | 6 (20.0) | 14 (15.7) | 3 (7.9) | 17 (21.0) | ||
| No | 24 (80.0) | 75 (84.3) | 35 (92.1) | 64 (79.0) | ||
| Periodontal condition | 0.369 | 0.068 | ||||
| Well | 11 (36.7) | 41 (46.1) | 12 (31.6) | 40 (49.4) | ||
| Poor | 19 (63.3) | 48 (53.9) | 26 (68.4) | 41 (50.6) | ||
| Tumor size, cm | 0.011a | 0.141 | ||||
| <2.9 | 18 (60.0) | 30 (33.7) | 19 (50.0) | 29 (35.8) | ||
| ≥2.9 | 12 (40.0) | 59 (66.3) | 19 (50.0) | 52 (64.2) | ||
| Treatment | <0.001a | 0.848 | ||||
| None | 3 (10.0) | 8 (9.0) | 4 (10.5) | 7 (8.6) | ||
| Surgery | 11 (36.7) | 30 (33.7) | 13 (34.2) | 28 (34.6) | ||
| Chemotherapy + radiotherapy | 0 (0.0) | 10 (11.2) | 2 (5.3) | 8 (9.9) | ||
| Comprehensive | 16 (53.3) | 41 (46.1) | 19 (50.0) | 38 (46.9) | ||
a
P<0.05.
b
According to the 7th American Joint Committee on Cancer/Union for International Cancer Control staging system. P-values were determined using χ2 or Fisher's exact tests. CXCL2, C-X-C motif chemokine ligand 2; TANs, tumor-associated neutrophils.